Format

Send to

Choose Destination
BMJ Case Rep. 2017 Aug 22;2017. pii: bcr-2017-221166. doi: 10.1136/bcr-2017-221166.

Zoster vaccine-associated primary varicella infection in an immunocompetent host.

Author information

1
Department of Internal Medicine, Yale-New Haven Hospital, New Haven, Connecticut, USA.
2
Department of Dermatology, Yale-New Haven Hospital, New Haven, Connecticut, USA.
3
Department of Pathology & Cell Biology, Columbia University College of Physicians & Surgeons, New York, New York, USA.
4
Department of Pediatrics, Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
5
Department of Medicine, Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA.

Abstract

A 64-year-old immunocompetent man developed a widespread pruritic and vesicular rash 2 weeks after receiving the zoster vaccine (Zostavax). He had fever, bandaemia with normal total white blood cell count and mild transaminitis. PCR testing of serum and skin was positive for varicella zoster virus (VZV), while serum VZV IgG was negative. The analysis of single nucleotide polymorphism by PCR and sequencing from the skin swab was consistent with the vaccine strain. The patient received 1 week of intravenous acyclovir and was discharged after all lesions had crusted. He continues to do well on follow-up with no significant complications.

KEYWORDS:

immunological products and vaccines; safety; skin; unwanted effects / adverse reactions; vaccination/immunisation

PMID:
28830902
PMCID:
PMC5624100
DOI:
10.1136/bcr-2017-221166
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center